Brazil

The Brazil­ian phar­ma­ceu­ti­cal mar­ket ranks first in Latin Amer­i­ca, with a total rev­enue exceed­ing US $26 billion per year, and demand will con­tinue to rise by about 15% annu­ally. Bet­ter income dis­tri­b­u­tion and social pro­grams are granting more and more of Brazil’s 191 million people access to health ser­vices and med­i­cines.

The Brazilian phar­ma­ceu­ti­cal indus­try has increased its pro­duc­tion by 50% within the last five years, but it still strongly relies on for­eign raw mate­ri­als and imports worth more than US $2 billion per year. Brazil also has a very dynamic bio-e­quiv­a­lent generic sec­tor, which accounts for 20% of the total market; in the last two years, for­eign pro­duc­ers have started actively and successfully pen­e­trat­ing this area.

Currently, Brazil has five lead­ing phar­macy chains that offer strong com­pe­ti­tion: Drog­a­ria São Paolo, Drog­a­rias Pacheco and Dro­gasil, which includes Droga Raia and Raia Dro­gasil.

CPC Press Releases on Brazil:

All football? Will the World Cup take over the “B” of BRIC countries?